Pfizer Inc (PFE) announced an update on their ongoing clinical study.
9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in ...
Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...
Hosted on MSN
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...
Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus by 89%. The company also ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results ...
-- Global pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection Depo-Provera (DMPA), is facing a Multidistrict Litigation (MDL No. 3140) in the USA being brought on ...
FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results